Cargando…

The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study

BACKGROUND: We evaluated the efficacy of fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, in patients with chronic migraine (CM) with and without medication overuse (MO). METHODS: In a 12-week, phase 3 trial, patients with CM were randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silberstein, Stephen D., Cohen, Joshua M., Seminerio, Michael J., Yang, Ronghua, Ashina, Sait, Katsarava, Zaza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507645/ https://www.ncbi.nlm.nih.gov/pubmed/32958075 http://dx.doi.org/10.1186/s10194-020-01173-8

Ejemplares similares

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study
por: Lipton, Richard B., et al.
Publicado: (2021)

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
por: Lipton, Richard B., et al.
Publicado: (2020)

Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
por: Pazdera, Ladislav, et al.
Publicado: (2021)

Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study
por: Goadsby, Peter J., et al.
Publicado: (2020)

Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine
por: Ashina, Messoud, et al.
Publicado: (2021)

Effect of fremanezumab on quality of life and productivity in patients with chronic migraine
por: Lipton, Richard B., et al.
Publicado: (2020)

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial
por: Tepper, Stewart J., et al.
Publicado: (2019)

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
por: Driessen, Maurice T., et al.
Publicado: (2022)

Fremanezumab for migraine
Publicado: (2020)

Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials
por: Silberstein, Stephen D., et al.
Publicado: (2021)

Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
por: Spierings, Egilius L. H., et al.
Publicado: (2021)

Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
por: Diener, Hans Christoph, et al.
Publicado: (2022)

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
por: Saigoh, Kazumasa, et al.
Publicado: (2023)

Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review
por: Rhyne, Christopher, et al.
Publicado: (2023)

Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
por: Driessen, Maurice T., et al.
Publicado: (2022)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
por: Root, Shane, et al.
Publicado: (2023)

Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine
por: Friedman, Deborah I., et al.
Publicado: (2020)

Fremanezumab in the treatment of migraines: evidence to date
por: Robblee, Jennifer, et al.
Publicado: (2019)

Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
por: Saigoh, Kazumasa, et al.
Publicado: (2023)

Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Imai, Noboru, et al.
Publicado: (2023)

No “Wearing‐Off Effect” Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long‐Term Study
por: Blumenfeld, Andrew M., et al.
Publicado: (2020)

Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study
por: Ashina, Messoud, et al.
Publicado: (2021)

Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
por: McAllister, Peter, et al.
Publicado: (2021)

An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
por: Urits, Ivan, et al.
Publicado: (2020)

Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma
por: Kawamura, Shin, et al.
Publicado: (2022)

From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries
por: Allena, Marta, et al.
Publicado: (2009)

Fremanezumab for migraine prevention: more effective, less costly
Publicado: (2020)

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention
por: Katsuki, Masahito, et al.
Publicado: (2023)

Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid
por: Ferrari, Michel D., et al.
Publicado: (2022)

Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine
por: Fiedler‐Kelly, Jill B., et al.
Publicado: (2019)

Reaching the Nadir of Medication Overuse in Chronic Migraine
por: Onan, Dilara, et al.
Publicado: (2022)

Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
por: McAllister, Peter, et al.
Publicado: (2022)

Defining the Differences Between Episodic Migraine and Chronic Migraine
por: Katsarava, Zaza, et al.
Publicado: (2011)

OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients without medication overuse
por: Diener, HC, et al.
Publicado: (2013)

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days
por: VanderPluym, Juliana, et al.
Publicado: (2018)

Increased activity of serotonin uptake in platelets in medication overuse headache following regular intake of analgesics and triptans
por: Ayzenberg, Ilya, et al.
Publicado: (2008)

Increased activity of serotonin uptake in platelets in medication overuse headache following regular intake of analgesics and triptans
por: Ayzenberg, Ilya, et al.
Publicado: (2008)

Chronic migraine plus medication overuse headache: two entities or not?
por: Negro, Andrea, et al.
Publicado: (2011)

Withdrawal failure in patients with chronic migraine and medication overuse headache
por: D’Amico, Domenico, et al.
Publicado: (2021)

Medication-overuse headache: a widely recognized entity amidst ongoing debate
por: Vandenbussche, Nicolas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rcsjr1f7j8tnh1log89ifda8qu